Cancer patient registry software market overview by on-premise and cloud-based models. Report aims at estimating cancer patient registry software size and future growth potential of the market across different segments, such as type, deployment model, database, functionality, end user, and region.
Cancer patient registry software market is projected to reach USD 91 million by 2024 from USD 56 million in 2019, at a CAGR of 10.4% during forecast period. Factors like increasing prevalence of cancer, favorable government initiatives, rising pressure to improve quality of care and reduce healthcare costs, rising adoption of EHRs, & growing use of cancer patient registry data for post-marketing surveillance are driving the growth of this market.
Download Free PDF Brochure Now on Cancer Registry Software Market Report at http://www.rnrmarketresearch.com/contacts/request-sample?rname=2075145 .
Cancer patient registry software market is segmented into commercial and public databases. The commercial databases segment dominated this market in 2018 owing to the ease of expansion of these databases, which allows a large user base to access, add, or modify information simultaneously. Also, owing to the advantages offered by commercial databases, a large number of pharmaceutical and medical device companies are opting for these databases.
Cancer patient registry software market report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cancer patient registry software market and its sub segments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
The on-premise model segment dominated this market in 2018 primarily due to the higher adoption of on-premise solutions among end users as a result of advantages such as high security, low risk of external attacks and data breaches, and control over software upgrades. Furthermore, the report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
More Information on Cancer Patient Registry Software Market Research Report Now at http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=2075145 .
North America was largest regional for cancer patient registry software market. This market is also estimated to grow at a higher CAGR during the forecast period. High growth of this regional market can be attributed to high burden of cancer, government funding initiatives to encourage development of cancer registries, high investments in healthcare IT, presence of major cancer registry software-developing players, & high adoption rate of these solutions in region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 28%; Tier 2- 19%; and Tier 3- 53%
- By Designation: C-level- 51%; D-level- 28%; and Others-21%
- By Region: North America-70%; Europe- 30%
Prominent players in Cancer patient registry software market are include Elekta (Sweden), Electronic Registry Systems, Inc. (US), Onco, Inc. (US), C/NET Solutions (US), Rocky Mountain Cancer Data Systems (US), and McKesson Corporation (US). It is highly consolidated in nature with a limited number of players operating in it.
Download the Complete Report on “Cancer Registry Software Market by Type, Delivery, Database, Functionality, End User, Region – Global Forecast to 2024” report at http://www.rnrmarketresearch.com/contacts/purchase?rname=2075145 .
The cancer patient registry software market is segmented into standalone and integrated software. The standalone software segment accounted for a larger share in 2018 primarily due to the significant use of standalone software by government organizations & TPAs for population health management (due to its adaptability and interoperability). Research centers use cancer patient registry software primarily to track patients who are eligible for clinical trials and product development.
The cancer patient registry software market is segmented into private payers; hospitals & medical practices; research centers; pharmaceutical, biotechnology, & medical device companies; and government organizations & third-party administrators. The research centers segment is estimated to grow at the highest CAGR during the forecast period.